Cancer immunotherapy is not a standard in clinical treatment of tumors, while first attempts were made several years ago. The appearance of tumor specific antigens (TSA) e.g. Bcr/abl, or tumor associated antigens (TAA) in cancer cells may be used theoreticaly in cancer therapy. Tumor cells in transformation process accumulate products of oncogenes and/or loss the functional products of tumor suppressor genes. This processes change intracellular signaling roads regulating cell proliferation and/or apoptosis of cancer cells and effect the tumor growth progression.